Cassava Sciences, Inc. (SAVA)
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases.
Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease.
The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019.
Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.
6801 N Capital Of Texas Highway, Building 1; Suite 300
Austin, Texas 78731
|Fiscal Year||January - December|
|Remi Barbier||Founder, Chairman, President and Chief Executive Officer|
|Eric J. Schoen||Chief Financial Officer|
|Dr. Nadav Friedmann M.D., Ph.D.||Chief Medical Officer and Director|
|Dr. James W. Kupiec M.D.||Chief Clinical Development Officer|
|Dr. George Thornton||Senior Vice President of Technology|
|Christopher Cook||Senior Vice President and General Counsel|
|Michael Zamloot||Senior Vice President of Technical Operations|
|Dr. Lindsay H. Burns Ph.D.||Senior Vice President of Neuroscience|
Latest SEC Filings
|Nov 22, 2022||8-K||Current Report|
|Nov 21, 2022||424B5||Filing|
|Nov 7, 2022||10-Q||Quarterly Report|
|Nov 7, 2022||8-K||Current Report|
|Nov 3, 2022||8-K||Current Report|
|Oct 27, 2022||8-K||Current Report|
|Sep 23, 2022||8-K||Current Report|
|Aug 4, 2022||10-Q||Quarterly Report|
|Aug 3, 2022||8-K||Current Report|
|Jul 29, 2022||424B5||Filing|